Liver Diseases Stem Cell Therapy Development
The liver is a vital organ responsible for numerous functions, including detoxification, metabolism, and the production of proteins. When the liver is damaged due to diseases, such as cirrhosis, hepatitis, or fatty liver disease, its ability to perform these functions is compromised. Stem cell therapy offers a potential solution to repair or replace damaged liver tissue. CD BioSciences offers stem cell therapy development services for liver diseases, based on out advanced technology and professional team.
Introduction into Liver Diseases
Liver disease refers to a broad spectrum of conditions that affect the liver, a vital organ responsible for numerous critical functions in the body. The liver is involved in processes such as detoxification, metabolism, protein synthesis, and the storage of nutrients.
Liver disease can result from various causes, including viral infections (such as hepatitis), excessive alcohol consumption, fatty liver disease, autoimmune disorders, genetic factors, and exposure to certain toxins or medications. Risk factors for liver disease include a history of alcohol abuse, obesity, a family history of liver disease, viral hepatitis infection (hepatitis B or C), and certain metabolic disorders.
Schematic diagram of stem cells in the treatment of common liver disease (Li, Shanshan et al., 2021)
CVDs are highly prevalent and have a significant impact on public health. They affect people of all ages, genders, and backgrounds. And they are responsible for a substantial proportion of global deaths, with coronary artery disease (CAD) and stroke being the most common causes. CVDs can lead to serious health complications, reduced quality of life, and increased healthcare costs.
Stem Cell Therapy for Liver Diseases
The immunomodulation and differentiation characteristics of stem cells play an important role in liver regeneration and repairment, therefore, stem cells are expected to transform the treatment of liver disease, especially end-stage liver disease. Followings are advantages and disadvantages of stem cells for treating liver diseases:
| Cell type | Advantages | Disadvantages |
| MSCs (Mesenchymal Stem Cells) |
Easy access from multiple tissues Rapid in vitro expansion Low ethical concerns Transplantation of autologous and allogenic cells due to low immunogenicity Beneficial immunomodulation Low risk of tumorigenicity Proof of safety in clinical trials |
Limited cell quantity Limited differentiation potential Undefined in situ phenotype Difficult to generate mature hepatocytes on a large scale Inconsistent therapeutic results |
| LSCs (Liver Stem Cells) |
Possible generation of cell lines Bidirectional differentiation into hepatocytes or cholangiocytes Low ethical concerns Low risk of tumorigenicity Transplantation of autologous and allogenic cells due to low immunogenicity Beneficial immunomodulation Proof of safety in animal experiment Proof of safety in a phase II clinical trial |
Access from the invasive hepatic biopsy or partial liver resection Undefined in situ phenotype Insufficient cell characterization Lack of standardized generation procedure Lack of adequate clinical trials |
| iPSCs (Induced Pluripotent Stem Cells) |
Easy access from multiple tissues Pluripotent differentiation potential Low ethical concerns Suitable for autologous transplantation Unlimited quantity |
Difficult to generate mature hepatocytes in large quantities Genomic instability Risk of tumorigenicity Risk of immunologic rejection Lack of standardized generation procedure |
| ESCs (Embryonic Stem Cells) |
Pluripotent differentiation potential Unlimited quantity Easy generation of cell lines Allows generation of off-the-shelf cell products ESCs-derived hepatocytes integrate into the host liver tissue |
Difficult to generate mature hepatocytes in large quantities Ethical concerns Risk of tumorigenicity Genomic instability Lack of availability Risk of immunologic rejection |
| PBSCs (Peripheral Blood Stem Cells) |
Defined in situ phenotype Low ethical concerns Suitable for autologous transplantation Rapid expansion after colony-stimulating factor mobilization Low risk of tumorigenicity |
Difficult access from peripheral blood Low cell quantity Limited differentiation potential Lack of adequate clinical trials |
Stem cells have many properties, including immunomodulation, differentiation into hepatocytes, and repairment of damaged tissues. With the continuous breakthroughs in stem cell isolation, gene editing, stem cell culture, transplantation, tracking, bio-artificial liver construction, tissue-engineered liver and other stem cell-related fields, stem cell will be widely used in the treatment of liver diseases.
Our Services
CD BioSciences offers stem cell therapy development service for spinal cord injury based on our advanced technology and professional team. Our services are included but not limited as follows:
- Alagille Syndrome
- Alcoholic Liver Disease (ALD)
- Alpha-1 Antitrypsin Deficiency
- Autoimmune Hepatitis
- Biliary Atresia
- Budd-Chiari Syndrome
- Congenital Hepatic Fibrosis
- Crigler-Najjar Syndrome
- Focal Nodular Hyperplasia (FNH)
- Glycogen Storage Diseases (e.g., Type I, III)
- Hemochromatosis
- Hepatic Adenomas
- Hepatic Encephalopathy
- Hepatitis (various types)
- Liver Abscesses
- Liver Cirrhosis
- Liver Cysts (Polycystic Liver Disease)
- Liver Failure
- Liver Fibrosis
- Liver Granulomas
- Liver Hemangioma
- Liver Metastases (secondary liver tumors)
- Liver Tumors
- Neonatal Hemochromatosis
- Non-Alcoholic Fatty Liver Disease (NAFLD)
- Nonalcoholic Steatohepatitis (NASH)
- Polycystic Liver Disease
- Primary Biliary Cirrhosis (PBC)
- Primary Sclerosing Cholangitis (PSC)
- Progressive Familial Intrahepatic Cholestasis (PFIC)
- Wilson's Disease
As a pioneer in biotechnology, CD BioSciences has grown into one of the largest independent biotechnology companies in the world. CD BioSciences is committed to providing professional and efficient service to our customers around the world. If you are interested in our service, please contact us.
Reference
- Li, Shanshan et al. "Stem cell transplantation for treating liver diseases: progress and remaining challenges." American journal of translational research vol. 13,5 3954-3966. 15 May. 2021
For research use only, not for clinical use.
